BioSpace News Archive

KidneyCure Ltd, a biotech company developing a novel cell-therapy technology for treating advanced chronic kidney disease, is expanding its circle of investors. The comapny has completed a round of financing from Aurum Ventures, a venture capital firm, and Direct Insurance Financial Investments.

- Roivant plans to initiate Phase 2 clinical trial in 2019

Milkshake promotion in honor of Children’s Day

Indivior PLC (LON: INDV) today announced that PERSERISTM(risperidone) for extended-release injectable suspension is now available in the United States. PERSERIS is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults.

According to the latest research by the company, the global pharma-grade synthetic camphor market size is anticipated to be valued at US$ 532.0 Mn, by 2028 end.

reSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD)

Tiziana Life Sciences plc today announces the pricing of its underwritten initial public offering in the United States (the “Offering”) of 442,910 American Depositary Shares (“ADSs”), representing 4,429,100 new ordinary shares of nominal value £0.03 each in the capital of the Company (“Ordinary Shares”) at an initial public offering price of $9.90 per ADS, before underwriting discounts and commissions.

Alma, one of the top five global leaders of energy-based medical and aesthetic solutions, today announced it has completed the first step of acquiring its Israeli distributor Nova Medical, extending its business outreach and establishing a direct operation in Israel.